Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 4, 2026

Study Completion Date

January 4, 2026

Conditions
Colorectal NeoplasmsColorectal CancerBreast CancerBreast NeoplasmsOvarian CancerOvarian Neoplasm
Interventions
OTHER

Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures

Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.

Trial Locations (1)

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT02732860 - Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host | Biotech Hunter | Biotech Hunter